Rena Therapeutics

What Rena Therapeutics does

Rena Therapeutics Inc. (レナセラピューティクス株式会社) is a privately held Japanese biotechnology company founded in January 2015 as a university spin-off from Tokyo Medical and Dental University (now Institute of Science Tokyo) to commercialize Heteroduplex Oligonucleotide (HDO) technology invented by Prof. Takanori Yokota and colleagues. The company is headquartered in Tokyo (Otemachi Financial City) with an R&D laboratory at Shonan Health Innovation Park in Fujisawa, Kanagawa, and employed 23 staff as of April 1, 2026. HDO is described as a third-generation nucleic acid drug platform that addresses three persistent limitations of conventional antisense therapeutics — extra-hepatic delivery, off-target toxicity (including hepatotoxicity and coagulation effects), and blood stability — by pairing an antisense strand (DNA, Gapmer, or PMO) with an RNA carrier strand that is cleaved intracellularly by RNase H, and by attaching a ligand to the carrier strand for receptor-mediated targeted delivery to specific tissues (skeletal muscle, myocardium, immune cells, CNS, lungs, kidneys). Rena also holds an exclusive inbound license (October 2021) for stereo-controlled boranophosphate oligomer technology from Tokyo University of Science.

The company operates three business lines: (1) licensing of HDO platform technology and intellectual property to pharmaceutical and biotech partners, (2) collaborative R&D in which Rena designs HDO compound libraries for customer targets and advances joint programs to lead candidate selection, and (3) manufacturing and sale of research-use HDO reagents distributed through channel partners Nippon Shokubai Co., Ltd. (corporate customers, domestic and international) and Nippon Gene Material Co., Ltd. (Japanese academia). Named licensees and partners include Takeda Pharmaceutical (five license agreements from 2018 through March 2025), Ionis Pharmaceuticals (non-exclusive license, December 2018), Nippon Shokubai (joined the group in November 2019; separate license agreement February 2023), and Nippon Gene Material (license December 2022). The company is part of the Nippon Shokubai Group and has received non-dilutive funding through Japan's AMED programs, including selection in February 2026 for the FY2025 'Drug Development Using Next-generation Drug-Delivery System' project in collaboration with multiple Japanese universities.

Name

Rena Therapeutics

Legal name

レナセラピューティクス株式会社

Website

https://renatherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Rena Therapeutics is a Tokyo-based Japanese biotech founded in 2015 as a Tokyo Medical and Dental University spin-off that licenses its HDO (Heteroduplex Oligonucleotide) nucleic acid drug platform, conducts collaborative R&D, and sells research-use HDO reagents to pharmaceutical partners including Takeda and Ionis.

Ownership category

akta.pro rank

Product category

Nucleic Acid Therapeutics Platform

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• Nucleic acid therapeutics
• Antisense oligonucleotide platform
• Drug delivery technology
• Oligonucleotide licensing
• RNA therapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing: Licensing out HDO technology and related intellectual property to pharmaceutical and biotech companies.
2. Collaborative R&D: Joint research and development with customers where Rena designs and provides HDO compounds, advancing collaborative R&D to identify lead HDO candidates.
3. HDO Manufacturing: Manufacturing, supply, and sale of HDO compounds for target genes exclusively for research and development purposes. Sales through channel partners Nippon Shokubai (corporate) and Nippon Gene (academia).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Rena Therapeutics develops and commercializes its proprietary Heteroduplex Oligonucleotide (HDO) technology — a third-generation nucleic acid drug platform enabling targeted gene control in organs beyond the liver via systemic administration. The company operates three business lines: (1) licensing HDO technology and intellectual property to pharmaceutical partners, (2) collaborative R&D services to design HDO compounds and identify lead candidates, and (3) manufacturing and supply of HDO compounds exclusively for research and development use.

Product overview

Rena Therapeutics offers a unified platform centered on Hetero-Duplex Oligonucleotide (HDO) Technology — a third-generation nucleic acid drug platform enabling targeted gene knockdown and exon skipping via ligand-conjugated delivery. The portfolio consists of the HDO Technology Platform as the core, supplemented by ligand library development for multi-organ targeting (lungs, kidneys, skeletal muscle, cardiac muscle, immune cells, CNS), and an exclusive stereo-controlled boranophosphate technology. Services include licensing, collaborative R&D, and HDO manufacturing for research use. The company operates through three business lines: licensing IP, joint research, and HDO compound supply/manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• HDO (Hetero-Duplex Oligonucleotide) Technology Platform Proprietary third-generation nucleic acid drug platform consisting of an antisense strand (DNA, Gapmer, or PMO), a carrier strand (RNA), and a ligand. Enables targeted gene knockdown and exon skipping via RNase H-dependent and independent mechanisms for nucleic acid therapeutics development targeting organs beyond the liver.
• HDO Technology Licensing Business Out-licensing of the HDO platform technology and improved intellectual property to pharmaceutical and biotech companies for use in nucleic acid drug discovery. Customers include Takeda Pharmaceutical, Ionis Pharmaceuticals, and Nippon Shokubai.
• Collaborative R&D Services Joint research and development engagements in which Rena Therapeutics designs and supplies HDO compound libraries for target genes and advances collaborative research to identify lead HDO candidates with pharmaceutical partners.
• HDO Manufacturing for Research Use Manufacture, supply, and sale of HDO compounds for target genes exclusively for research and development purposes. Distributed through Nippon Shokubai Co., Ltd. for corporate customers and Nippon Gene Material Co., Ltd. for domestic academic customers.

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core.

• Japan Agency for Medical Research and Development (AMED)coreStrategic or Co-development Partner · 18 February 2026FY2025 research project on next-generation drug discovery using advanced drug delivery systems. Collaboration with Institute of Science Tokyo, Graduate School of The University of Tokyo, and Graduate School of Kobe University.
• Nippon Shokubai Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 21 February 2023License agreement for HDO technology. Nippon Shokubai distributes HDO products to both corporate and academic customers. Rena Therapeutics joined the Nippon Shokubai Group in November 2019.
• Nippon Gene Material Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 20 December 2022License agreement for distribution of HDO products to domestic academic institutions.
• Tokyo University of SciencecoreTechnology or Integration · 28 October 2021Collaboration on boranophosphate antisense nucleic acid (PB-ASO) technology development with stereo-controlled phosphorus atom chemistry. Part of AMED drug discovery project.
• Takeda Pharmaceutical Company LimitedcoreOEM/ Whitelabel/ Licensing Partner · 24 December 2018Multiple license agreements signed (December 2018, December 2020, August 2022, July 2023, March 2025) for HDO technology. The expanding relationship demonstrates Takeda's continued interest in HDO platform applications.
• Ionis Pharmaceuticals, Inc.coreOEM/ Whitelabel/ Licensing Partner · 24 December 2018Non-exclusive license agreement signed December 2018 for HDO technology.
• Tokyo Medical and Dental UniversitycoreStrategic or Co-development Partner · 25 February 2015University spin-off relationship. HDO technology invented by Prof. Takanori Yokota and colleagues at Tokyo Medical and Dental University. Rena Therapeutics established as a university venture from this institution.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Emerging players

• Stoke Therapeutics: Clinical-stage antisense oligonucleotide company using TANGO splice-modulation for genetic diseases. Comparable to Rena because HDO also supports exon skipping / splice modulation mechanisms and serves CNS and other extra-hepic indications.
• Arcturus Therapeutics: Clinical-stage RNA medicines company developing LNP-delivered mRNA, siRNA, and antisense therapeutics. Comparable to Rena because both pursue RNA-targeting modalities with non-liver delivery as a key differentiator and a mix of partnership and internal programs.
• Bio-Path Holdings: Clinical-stage nucleic acid therapeutics company developing DNA-based RNAi and antisense products. Comparable to Rena because it is an early-to-mid-stage platform company pursuing extra-hepatic nucleic acid delivery with a similar licensing/partnership go-to-market posture.

Others

• Takeda Pharmaceutical: Japan's largest pharmaceutical company and Rena's largest disclosed licensing counterparty. Comparable to Rena because Takeda is the most consequential customer/partner for the HDO platform and shares the same Japanese pharma/biotech ecosystem.
• Nippon Shokubai: Japanese chemical company and Rena's corporate parent/Group member since 2019; HDO distribution and licensing partner. Comparable to Rena as the industrial/distribution backbone through which Rena's HDO products reach corporate and academic customers globally.

Direct peers

• Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with a stereopure PRISM platform targeting RNA via ASO and siRNA mechanisms. Comparable to Rena because both companies compete on next-generation stereochemistry and delivery to address extra-hepatic tissues.
• Ionis Pharmaceuticals: Global leader in antisense oligonucleotide therapeutics and the original commercializer of ASO technology. Comparable to Rena because Ionis is itself a licensee of HDO and operates the same category — nucleic acid-based RNA-targeting therapeutics — making it the closest functional peer.

Regional players

• Eisai: Major Japanese pharmaceutical company investing in oligonucleotide and RNA-targeted drug discovery. Comparable to Rena as a potential future Japanese licensor/partner and as a benchmark for how Japan-headquartered pharma evaluates next-generation nucleic acid platforms.

Broad incumbents

• Sarepta Therapeutics: Commercial-stage RNA-targeted therapeutics company focused on genetic diseases including exon-skipping PMO therapies (eteplirsen, golodirsen). Comparable to Rena because Sarepta operates in overlapping nucleic acid mechanisms (PMO/exon skipping) and extra-hepatic tissue targeting (muscle).
• Alnylam Pharmaceuticals: Global leader in RNA interference therapeutics with extensive GalNAc-conjugated siRNA portfolio. Comparable to Rena because Alnylam sets the benchmark for nucleic acid drug delivery, including extra-hepatic targets, against which HDO's differentiation is measured.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rena Therapeutics